title: Experience with prothrombin complex for the emergent reversal of anticoagulation in rural geriatric trauma patients.
abstract: BACKGROUND
  Therapeutic anticoagulation in the geriatric trauma population is increasingly common. Fresh frozen plasma, while the criterion standard for correction, has limited availability and associated transfusion risks. We examined our use of prothrombin complex concentrate for immediate reversal of therapeutically anticoagulated geriatric trauma patients.
  
  
  METHODS
  This was a 1-year, retrospective review of 25 geriatric trauma patients who received either fresh frozen plasma alone or prothrombin complex concentrate and met the inclusion criteria of age >55 years, current warfarin use, and an admission international normalized ratio of >1.5. Fifteen patients received prothrombin complex concentrate and 10 patients received fresh frozen plasma alone. We examined demographics, laboratory values, and blood product use.
  
  
  RESULTS
  The mean ages were similar (77 vs 80 years). Patients had similar mean Injury Severity Score (19.1 vs 19.2). Survivor duration of hospital stay (7.7 vs 9.5; P = .37) and duration of stay in the intensive care unit (4.4 vs 7.1; P = .25) trended positively in the prothrombin complex concentrate group. The prothrombin complex concentrate group received fewer units of fresh frozen plasma (1.6 [range, 0-6] vs 2.7 [range, 2-4]; P = .05), with a greater decrease in international normalized ratio (51% vs 43%; P = .05). Six patients (40%) in the prothrombin complex concentrate group avoided fresh frozen plasma transfusion altogether.
  
  
  CONCLUSIONS
  Prothrombin complex may be used safely and effectively to reverse emergently anticoagulation in geriatric trauma patients.
authors.affiliation: Department of Surgery, Division of Acute Care Surgery, University of Missouri School of Medicine, University of Missouri, Columbia, MO 65212, USA.
authors.forename: Jacob A
authors.initials: JA
authors.lastname: Quick
authors.forename: Ashley N
authors.initials: AN
authors.lastname: Bartels
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Coughenour
authors.forename: Stephen L
authors.initials: SL
authors.lastname: Barnes
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D003422:Critical Care; D006801:Humans; D019934:International Normalized Ratio; D007902:Length of Stay; D008875:Middle Aged; D010949:Plasma; D012189:Retrospective Studies; D012424:Rural Population; D014193:Trauma Centers; D014859:Warfarin / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D014947:Wounds and Injuries / Q000097:blood* / Q000628:therapy*
chemical_list: D000925:Anticoagulants; D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D014859:Warfarin